secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0000950170-23-017472
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intellia dosed first patient in NTLA-2002 Phase 2; Q1 net loss $103.1M, cash $1.2B
--------------------------------------------------------------------------------

- Dosed first patient in global Phase 2 study of NTLA-2002 for HAE; enrollment completion expected 2H 2023.
- Plans to submit IND in mid-2023 for global pivotal trial of NTLA-2001 for ATTR-CM; study initiation expected by year-end 2023.
- Cash, cash equivalents and marketable securities of $1.2B as of March 31, 2023; net loss $103.1M for Q1 2023.
- R&D expenses decreased to $97.1M from $133.1M YoY, partially due to absence of Rewrite acquisition expense.
- Collaboration revenue increased to $12.6M from $11.3M; G&A expenses rose to $27.4M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000095017023017472/0000950170-23-017472-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000095017023017472/ntla-20230504.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-017472

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer